Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238270 | 0.85 | BUB1 (0.48) | ALDH1A1KMT2AKDM4ESMN1; SMN2TSHR | |
| SCHEMBL4889582 | 0.75 | BUB1 (0.35) | BUB1 | |
| SCHEMBL24413554 | 0.74 | ALDH1A1 (0.49) | ALDH1A1KMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL10001994 | 0.72 | ALDH1A1 (0.48) | ALDH1A1KMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL7713810 | 0.71 | ALDH1A1 (0.47) | ALDH1A1KMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL871448 | 0.70 | ALDH1A1 (0.50) | ALDH1A1KMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL16720987 | 0.69 | ALDH1A1 (0.47) | ALDH1A1KMT2AKDM4EMEN1GAA | |
| SCHEMBL28201234 | 0.69 | ALDH1A1 (0.47) | ALDH1A1KMT2AKDM4EMEN1GAA | |
| SCHEMBL23426079 | 0.68 | ALDH1A1 (0.46) | ALDH1A1KMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL10337538 | 0.68 | BUB1 (0.49) | ALDH1A1KMT2AKDM4EMEN1BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093473-A1 | Spiro-benzimidazoles as inhibitors of gastric acid secretion | NYCOMED GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
| EP-1899338-A1 | SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION | Nycomed GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| US-20070244154-A1 | Substituted Tricyclic Benzimidazoles | ALTANA PHARMA AG (DE) | 2007-10-18 | — | — | US | disclosed |
| EP-1758900-B1 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1758900-A1 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES | Altana Pharma AG (DE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006134111-A1 | SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION | NYCOMED GMBH (DE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2005121139-A1 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244154-A1 | Substituted Tricyclic Benzimidazoles | VIP, GIPR, SLC10A2 | ALDH1A1 510/4885KMT2A 3731/4885KDM4E 2926/4885 |
| US-20090093473-A1 | Spiro-benzimidazoles as inhibitors of gastric acid secretion | GIPR, PGC, SLC10A2 | ALDH1A1 187/4885KMT2A 4175/4885KDM4E 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.